AltheRx Pharmaceuticals Inc.
Safe and highly selective therapy for IBS and OAB
This article was originally published in Start Up
AltheRx Pharmaceuticals Inc. acquired its lead compound, solabegron, from GlaxoSmithKline in March 2011. Solabegron relaxes smooth muscles by stimulating beta-3 adrenoceptors, a novel mechanism compared with currently available treatments for overactive bladder and irritable bowel syndrome, the first two indications that AltheRx is targeting.
You may also be interested in...
Private companies developing drugs for gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome hope to take advantage of a resurging interest in the space after linaclotide developer Ironwood Pharmaceuticals has shown its novel, locally acting guanylate cyclise type-C agonist is efficacious in four Phase III trials. We profile four such hopefuls in this issue: Altheus Therapeutics, AltheRx Pharmaceuticals, Aldrex and Second Genome.
Ardelyx Inc. is designing drugs to interact with specific proteins that are found in the intestinal lining and control mineral transport. The company’s most advanced candidate, RDX5791, is meant to block sodium by selectively inhibiting NHE3, a sodium transporter on the surface of the intestinal lining. Preventing sodium absorption may increase the amount of fluid in the lumen of the gut, thus Ardelyx is developing RDX5791 as a treatment for irritable bowel syndrome with constipation.
If you can’t beat them, join them. Looks like the backers of Altheus Therapeutics Inc. see sound business sense in this homily: the start-up is working to create a potent new treatment for ulcerative colitis by combining N-acetylcysteine, an anti-inflammatory compound, with the aspirin derivative mesalamine, which for decades has been the front-line therapy for the condition.